From the Journals

Dual Therapy Boosts Weight Loss in Trial 

A phase 2 trial found greater results with combined bimagrumab and semaglutide than with either therapy alone 

Share

  • 1

    Phase 2 trial on obesity treatment combination.

  • 2

    507 adults with obesity or overweight.

  • 3

    Bimagrumab + semaglutide led to significant weight loss.

  • 4

    Highest-dose group lost 24.2 kg by week

  • 5

    Combination preserved lean body mass effectively.

  • 6

    Metabolic improvements noted in glycated hemoglobin levels.

  • 7

    Safety profiles consistent with known effects.

  • 8

    Further trials needed for long-term efficacy and safety.

Original Source(s)

Dual Therapy Boosts Weight Loss in Trial 

  • by Henry Thomas

  • March 16, 2026

Related Content

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Elevated PFAS Linked to Changes in Blood Lipids 

Serum lipid profiling reveals PFAS-linked shifts in triglyceride and membrane lipid species 

  • March 17, 2026

  • 2 min
Oral Bacteria Linked to Bone Loss in Mouse Study

Researchers find periodontitis-associated microbiota altered gut metabolism and increased osteoclast activity in mice.

  • March 16, 2026

  • 2 min